Respiratory Virus Infection Drugs Market Size, Share and Forecast 2032

Respiratory Virus Infection Drugs Market

Respiratory Virus Infection Drugs Market By Drug Type (Antibiotics, Nasal Decongestants, Non-Steroidal Anti-Inflammatory Drugs, and Cough Suppressants), By Infection Type (Respiratory Syncytial Virus Infection, Adenovirus Infection, Influenza Virus Infection, Para influenza Virus Infection, and Rhinovirus Infection), By Distribution Channel(Hospital Pharmacies, Clinics, Retail Pharmacies, and Drug Stores ), By Route of Administration (Oral and Parenteral), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024-2032

Category: Pharmaceutical Report Format : PDF Pages: 140 Report Code: ZMR-6584 Published Date: Nov-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 22.37 Billion USD 48.59 Billion 9% 2023

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Type
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
    • 2.2. Respiratory Virus Infection Drugs Market: Snapshot
  • Chapter 3. Global Respiratory Virus Infection Drugs Market– Industry Analysis
    • 3.1. Respiratory Virus Infection Drugs Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Large-scale utilization of AI and machine learning in drug discovery activities is set to leverage respiratory virus infection drugs market expansion over 2021-2028.
      • 3.2.2. Escalated use of combined drug treatment is slated to boost success rate of treating respiratory virus infection through anti-viral agents such as anti-viral medicines. This, in turn, will promulgate elevation of respiratory virus infection drugs market size within next couple of years.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Drug Type
      • 3.4.2. Market attractiveness analysis By Infection Type
      • 3.4.3. Market attractiveness analysis By Route of Administration
      • 3.4.4. Market attractiveness analysis By Distribution Channel
  • Chapter 4. Global Respiratory Virus Infection Drugs Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Respiratory Virus Infection Drugs Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Respiratory Virus Infection Drugs Market– Drug Type Analysis
    • 5.1. Global Respiratory Virus Infection Drugs Market overview: By Drug Type
      • 5.1.1. Global Respiratory Virus Infection Drugs Market share, By Drug Type, 2020 and 2028
    • 5.2. Antibiotics
      • 5.2.1. Global Respiratory Virus Infection Drugs Market by Antibiotics, 2018–2028(USD Billion)
    • 5.3. Nasal Decongestants
      • 5.3.1. Global Respiratory Virus Infection Drugs Market by Nasal Decongestants, 2018–2028(USD Billion)
    • 5.4. Non-Steroidal Anti-Inflammatory Drugs
      • 5.4.1. Global Respiratory Virus Infection Drugs Market by Non-Steroidal Anti-Inflammatory Drugs, 2018–2028(USD Billion)
    • 5.5. Cough Suppressants
      • 5.5.1. Global Respiratory Virus Infection Drugs Market by Cough Suppressants, 2018–2028(USD Billion)
  • Chapter 6. Global Respiratory Virus Infection Drugs Market– Infection Type Analysis
    • 6.1. Global Respiratory Virus Infection Drugs Market overview: By Infection Type
      • 6.1.1. Global Respiratory Virus Infection Drugs Market share, By Infection Type, 2020 and 2028
    • 6.2. Respiratory Syncytial Virus Infection
      • 6.2.1. Global Respiratory Virus Infection Drugs Market by Respiratory Syncytial Virus Infection , 2018–2028(USD Billion)
    • 6.3. Influenza Virus Infection
      • 6.3.1. Global Respiratory Virus Infection Drugs Market by Influenza Virus Infection, 2018–2028(USD Billion)
    • 6.4. Para Influenza Virus Infection
      • 6.4.1. Global Respiratory Virus Infection Drugs Market by Para Influenza Virus Infection, 2018–2028(USD Billion)
    • 6.5. Rhinovirus Infection
      • 6.5.1. Global Respiratory Virus Infection Drugs Market by Rhinovirus Infection, 2018–2028(USD Billion)
    • 6.6. Adenovirus Infection
      • 6.6.1. Global Respiratory Virus Infection Drugs Market by Adenovirus Infection, 2018–2028(USD Billion)
  • Chapter 7. Global Respiratory Virus Infection Drugs Market– Route of Administration Analysis
    • 7.1. Global Respiratory Virus Infection Drugs Market overview: By Route of Administration
      • 7.1.1. Global Respiratory Virus Infection Drugs Market share, By Route of Administration, 2020 and 2028
    • 7.2. Oral
      • 7.2.1. Global Respiratory Virus Infection Drugs Market by Oral , 2018–2028(USD Billion)
    • 7.3. Parenteral
      • 7.3.1. Global Respiratory Virus Infection Drugs Market by Parenteral, 2018–2028(USD Billion)
  • Chapter 8. Global Respiratory Virus Infection Drugs Market overview: By Distribution Channel
    • 8.1.1. Global Respiratory Virus Infection Drugs Market share, By Distribution Channel, 2020 and 2028
    • 8.2. Hospital Pharmacies
      • 8.2.1. Global Respiratory Virus Infection Drugs Market by Hospital Pharmacies , 2018–2028(USD Billion)
    • 8.3. Drug Stores
      • 8.3.1. Global Respiratory Virus Infection Drugs Market by Drug Stores, 2018–2028(USD Billion)
    • 8.4. Retail Pharmacies
      • 8.4.1. Global Respiratory Virus Infection Drugs Market by Retail Pharmacies, 2018–2028(USD Billion)
    • 8.5. Clinics
      • 8.5.1. Global Respiratory Virus Infection Drugs Market by Clinics, 2018–2028(USD Billion)
  • Chapter 9. Company Profiles
    • 9.1. AstraZeneca
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. AbbVie
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. GlaxoSmithKline plc
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Development
    • 9.4. CHIESI Farmaceutici S.p.A.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Development
    • 9.5. Roche Diagnostics Limited
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. Orion Corporation
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development
    • 9.7. Cipla, Inc.
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Development
    • 9.8. Sanofi
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Development
    • 9.9. Merck & Co., Inc.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Development
    • 9.10. Boehringer Ingelheim International GmbH
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product Portfolio
      • 9.10.4. Business Strategy
      • 9.10.5. Recent Development
    • 9.11. Teva Pharmaceutical Industries Limited
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Product Portfolio
      • 9.11.4. Business Strategy
      • 9.11.5. Recent Development

Table Of Figures

List of Figures

1. Market research Type
2. Market research methodology
3. Global Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
4. Porter’s Five Forces Analysis
5. Global Respiratory Virus Infection Drugs Marketattractiveness, By Drug Type
6. Global Respiratory Virus Infection Drugs Marketattractiveness, By Route of Administration
7. Global Respiratory Virus Infection Drugs Marketattractiveness, By Infection Type
8. Global Respiratory Virus Infection Drugs Marketattractiveness, By Distribution Channel
9. Global Respiratory Virus Infection Drugs Marketshare by Drug Type ,2020 and 2028 (USD Billion)
10. Global Respiratory Virus Infection Drugs Marketby Antibiotics, 2018–2028(USD Billion)
11. Global Respiratory Virus Infection Drugs Marketby Nasal Decongestants, 2018–2028(USD Billion)
12. Global Respiratory Virus Infection Drugs Marketby Non-Steroidal Anti-Inflammatory Drugs, 2018–2028(USD Billion)
13. Global Respiratory Virus Infection Drugs Marketby Cough Suppressants, 2018–2028(USD Billion)
14. Global Respiratory Virus Infection Drugs Marketshare by Infection Type ,2020 and 2028 (USD Billion)
15. Global Respiratory Virus Infection Drugs Marketby Respiratory Syncytial Virus Infection  , 2018–2028(USD Billion)
16. Global Respiratory Virus Infection Drugs Marketby Influenza Virus Infection, 2018–2028(USD Billion)
17. Global Respiratory Virus Infection Drugs Marketby Para Influenza Virus Infection, 2018–2028(USD Billion)
18. Global Respiratory Virus Infection Drugs Marketby Rhinovirus Infection, 2018–2028(USD Billion)
19. Global Respiratory Virus Infection Drugs Marketby Adenovirus Infection, 2018–2028(USD Billion)
20. Global Respiratory Virus Infection Drugs Marketshare by Route of Administration ,2020 and 2028 (USD Billion)
21. Global Respiratory Virus Infection Drugs Marketby Oral,  2018–2028(USD Billion)
22. Global Respiratory Virus Infection Drugs Marketby Parenteral, 2018–2028(USD Billion)
23. Global Respiratory Virus Infection Drugs Marketshare by Distribution Channel ,2020 and 2028 (USD Billion)
24. Global Respiratory Virus Infection Drugs Marketby Hospital Pharmacies,  2018–2028(USD Billion)
25. Global Respiratory Virus Infection Drugs Marketby Retail Pharmacies, 2018–2028(USD Billion)
26. Global Respiratory Virus Infection Drugs Marketby Clinics, 2018–2028(USD Billion)
27. Global Respiratory Virus Infection Drugs Marketby Drug Stores, 2018–2028(USD Billion)
28. Global Respiratory Virus Infection Drugs Marketshare, by Region, 2020 and 2028
29. North America Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
30. Europe Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
31. Asia Pacific Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
32. Latin America Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
33. The Middle East and Africa Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)


Table Of Tables

List of Tables

1. Global Respiratory Virus Infection Drugs Market: snapshot
2. Drivers of the Respiratory Virus Infection Drugs Market: impact analysis
3. North America Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
4. North America Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
5. North America Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
6. North America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
7. The U.S. Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
8. The U.S. Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
9. The U.S. Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
10. The U.S. Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
11. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
12. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
13. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
14. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
15. Europe Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
16. Europe Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
17. Europe Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
18. Europe Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
19. UK Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
20. UK Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
21. UK Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
22. UK Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
23. France Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
24. France Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
25. France Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
26. France Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
27. Germany Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
28. Germany Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
29. Germany Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
30. Germany Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
31. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
32. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
33. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
34. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
35. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
36. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
37. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
38. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
39. China Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
40. China Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
41. China Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
42. China Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
43. Japan Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
44. Japan Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
45. Japan Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
46. Japan Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
47. India Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
48. India Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
49. India Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
50. India Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
51. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
52. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
53. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
54. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
55. Latin America Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
56. Latin America Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
57. Latin America Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
58. Latin America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
59. Brazil Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
60. Brazil Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
61. Brazil Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
62. Brazil Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
63. Rest of Latin America Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
64. Rest of Latin  America Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
65. Rest of Latin America Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
66. Rest of Latin  America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
67. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
68. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
69. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
70. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
71. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
72. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
73. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
74. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
75. South Africa Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
76. South Africa Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
77. South Africa Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
78. South Africa Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
79. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Drug Type  ,2018–2028(USD Billion)
80. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Infection Type  ,2018–2028(USD Billion)
81. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Route of Administration  ,2018–2028(USD Billion)
82. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
 
 

Methodology

FrequentlyAsked Questions

These drugs treat infections affecting the respiratory system. They help reduce symptoms and viral impact
The global Respiratory Virus Infection Drugs market is expected to be driven by the rising viral infection cases and global preparedness initiatives. R&D investment and demand for antiviral therapies support market growth.
According to study, the global Respiratory Virus Infection Drugs market size was worth around USD 22.37 Billion in 2023 and is predicted to grow to around USD 48.59 Billion By 2032.
The global Respiratory Virus Infection Drugs market is expected to grow at a Compound Annual Growth Rate (CAGR) of around CAGR 9% during the forecast period from 2024-2032.
The global Respiratory Virus Infection Drugs industry is projected to be challenged by Challenges include viral mutation risks, long clinical timelines, and resistance concerns.
The Opportunities include seasonal outbreaks, antiviral R&D investment, pandemic preparedness, and global healthcare demand will offer significant growth opportunities in the Respiratory Virus Infection Drugs market.
Broad-spectrum antivirals; host-targeted therapies; rapid development pipelines for emerging variants are the emerging trends and innovations impacting the Respiratory Virus Infection Drugs market.
The global Respiratory Virus Infection Drugs market is expected to be led by North America during the forecast period.
Some of the prominent players operating in the global Respiratory Virus Infection Drugs market are; AstraZeneca, AbbVie, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Roche Diagnostics Limited, Orion Corporation, Cipla, Inc., Sanofi, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, and Merck & Co., Inc. and others.
The report explores crucial aspects of the Respiratory Virus Infection Drugs market, including a detailed discussion of existing growth factors and restraints, while also browsing future growth opportunities and challenges that impact the market.
  • zion payment modes

List of Contents

Market InsightsOverviewGrowth DriversReport ScopeRegional LandscapeCompetitive LandscapeThe global Market is segmented as follows:

HappyClients